A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...
Future studies may look at targeting the CD40 pathway as a potential therapeutic target ORLANDO, DECEMBER 7, 2025 - Researchers at The University of Texas MD Anderson Cancer Center have characterized ...
Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment. While effective at activating the immune system to kill cancer ...
Cancer immunotherapy is a strategy that turns the patient’s own immune cells into a “search-and-destroy” force that attacks the tumor’s cells. The “search” immune cells are the dendritic cells, which ...
In a new study published in Science titled, “Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity,” researchers from St. Jude Children’s Research Hospital have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results